42,152 Shares in Embecta Corp. (NASDAQ:EMBC) Bought by Jennison Associates LLC

Jennison Associates LLC bought a new position in shares of Embecta Corp. (NASDAQ:EMBC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 42,152 shares of the company’s stock, valued at approximately $594,000.

Several other large investors have also bought and sold shares of EMBC. Vanguard Group Inc. grew its holdings in Embecta by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 7,213,992 shares of the company’s stock worth $95,730,000 after acquiring an additional 187,916 shares during the period. American Century Companies Inc. grew its holdings in Embecta by 0.6% during the 2nd quarter. American Century Companies Inc. now owns 3,163,073 shares of the company’s stock worth $39,538,000 after acquiring an additional 18,933 shares during the period. Bank of New York Mellon Corp grew its holdings in Embecta by 1.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 793,585 shares of the company’s stock worth $9,920,000 after acquiring an additional 12,424 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Embecta by 95.3% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 643,230 shares of the company’s stock worth $8,536,000 after acquiring an additional 313,951 shares during the period. Finally, AQR Capital Management LLC grew its holdings in Embecta by 136.2% during the 2nd quarter. AQR Capital Management LLC now owns 614,645 shares of the company’s stock worth $7,683,000 after acquiring an additional 354,454 shares during the period. 93.83% of the stock is owned by institutional investors.

Embecta Trading Down 1.3 %

Shares of Embecta stock opened at $13.82 on Monday. The business has a 50-day moving average price of $14.38 and a two-hundred day moving average price of $14.01. Embecta Corp. has a 1-year low of $9.93 and a 1-year high of $19.79. The company has a market cap of $797.44 million, a P/E ratio of 11.52 and a beta of 0.97.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.